AIMT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AIMT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Aimmune Therapeutics's shares outstanding for the quarter that ended in Jun. 2020 was 65.44 Mil.
Aimmune Therapeutics's quarterly shares outstanding increased from Mar. 2020 (65.22 Mil) to Jun. 2020 (65.44 Mil). It means Aimmune Therapeutics issued new shares from Mar. 2020 to Jun. 2020 .
Aimmune Therapeutics's annual shares outstanding increased from Dec. 2018 (62.14 Mil) to Dec. 2019 (63.78 Mil). It means Aimmune Therapeutics issued new shares from Dec. 2018 to Dec. 2019 .
The historical data trend for Aimmune Therapeutics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aimmune Therapeutics Annual Data | ||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 42.24 | 50.20 | 51.09 | 62.14 | 63.78 |
Aimmune Therapeutics Quarterly Data | ||||||||||||||||||||
Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 62.66 | 63.09 | 63.78 | 65.22 | 65.44 |
For the Biotechnology subindustry, Aimmune Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aimmune Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Aimmune Therapeutics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Aimmune Therapeutics (NAS:AIMT) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Aimmune Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Gregory Behar | director | C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472 |
Societe Des Produits Nestle S.a. | 10 percent owner | AVENUE NESTLE 55, VEVEY V8 CH-1800 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Andrew Oxtoby | officer: Chief Commercial Officer | 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Dallas Jayson Donald Alexander | director, officer: President and CEO | AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Stacey Denenberg Seltzer | director | C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Brett K Haumann | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Douglas T. Sheehy | officer: See Remarks | C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005-1884 |
Mark T Iwicki | director | 84 WATERFORD DRIVE, MARLBOROUGH MA 01752 |
Patrick G Enright | director | CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Mark Mcdade | director | C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040 |
Adelman Daniel C Md | officer: Chief Medical Officer | 23 WOODLEAF AVENUE, REDWOOD CITY CA 94061 |
Eric Bjerkholt | officer: Chief Financial Officer | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Sa Nestle | 10 percent owner | AVE NESTLE 55, CH-1800, VEVEY V8 |
Mary M. Rozenman | officer: See Remarks | AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005 |
From GuruFocus
By PRNewswire PRNewswire • 09-14-2020
By Business Wire Business Wire • 06-01-2020
By Marketwired Marketwired • 08-31-2020
By Business Wire Business Wire • 08-24-2020
By Business Wire Business Wire • 06-04-2020
By Marketwired Marketwired • 09-23-2020
By Business Wire Business Wire • 05-28-2020
By Business Wire Business Wire • 06-08-2020
By Business Wire Business Wire • 09-05-2020
By PRNewswire PRNewswire • 09-01-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.